Heart failure (HF) is a clinical syndrome based primarily on systolic or diastolic left-ventricular (LV) contractile dysfunction. The prognosis of chronic HF is poor, with about 50% of patients dying within 5 years after the initial diagnosis. There are different categories of HF, which are based on measurements of LV ejection fraction (LVEF). About half of HF patients are afflicted with HF with reduced ejection fraction (HFrEF) with an LVEF of <40%. In contrast, HF with preserved ejection fraction (HFpEF) is observed in roughly the other half of patients (LVEF ≥ 50%). Patients with an LVEF in the range of 40–49% represent a “gray area” that is defined as HF with mid-range ejection fraction (HfmrEF; [1]). The prevalence of HF in industrialized nations is increasing to more than 10% among people greater 70 years of age [2]. Statistically, about one in three individuals at 55 years of age will develop HF during their remaining lifespan [3]. The increase in HF can be explained by the rising prevalence of renal failure, arterial hypertension, chronic obstructive pulmonary disease (COPD), diabetes mellitus, and metabolic syndrome. These comorbidities are characterized by chronic inflammation and are of particular importance for patients with HFpEF [2]. Furthermore, the treatment of ischemic heart disease has significantly improved over the past few decades, which has increased the number of surviving HF patients.

In addition to playing a critical role in the development and progression of HFpEF and HFrEF [4, 5], the inflammatory response is also important for adverse remodeling processes following myocardial infarction (MI). The development of HF can also be directly immune-modulated, for example, following autoimmune or infectious triggers, i.e., viral infection. Following acute myocardial injury, the inflammatory response is required to induce the regenerative response, but sustained and chronic inflammation is detrimental. Based on the dichotomous role of inflammation in cardiac tissue, the modulation of inflammatory processes has been identified as a therapeutic approach. The pathomechanisms underpinning inflammation modulation for therapeutic benefit have been investigated in numerous studies and will be summarized in this review.

**HFpEF, endothelial dysfunction, and inflammation**

One hallmark of HFpEF is impaired LV relaxation as a consequence of altered composition of the extracellular matrix and decreased cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) signaling. From a mechanistic perspective, comorbidities promote systemic inflammation, which increases reactive oxygen species (ROS) production in cardiac endothelial cells and peroxynitrite (ONOO⁻) levels. The subsequent decrease in nitric oxide (NO) in endothelial cells impairs soluble guanylate cyclase (sGC) levels and PKG activity in adjacent cardiomyocytes. This promotes adverse LV remodeling and hypophosphorylation of titin, which impairs LV relaxation. Furthermore, monocytes infiltrate cardiac tissue under conditions of chronic inflammation and differentiate into macrophages, which augment myocardial inflammation. This also promotes fibrosis by differentiation of fibroblasts into myofibroblasts following transforming growth factor beta (TGF β) secretion by monocytes ([6]; Fig. 1).

Several studies provide mechanistic insight into the cardioprotective effects of NO/sGC/cGMP/PKG signaling. For example, pharmacological stimulation of sGC attenuates LV remodeling after MI in mice, decreases extracellular matrix protein production in human cardiac fibroblasts following TGFβ stimulation in vivo [7], and attenuates vascular dysfunction in diabetic rats [8]. Similarly, the endothelial NO synthase (eNOS) transcription enhancer AVE9488 improves cardiac remodeling after MI [9] and platelet NO availability and hyperactivity in HF [10]. Senescence-accelerated-prone mice (SAMP) develop manifest HFpEF when subjected to a high-salt, high-fat diet, which is characterized by endothelial cell dysfunction and fibrosis. These studies highlight the contribution of endothelial cell dysfunction on the age-dependent increase in HFpEF [11]. Furthermore, increased insulin-like growth factor-1 (IGF-1) activity following growth hormone stimulation attenuates age-dependent endothelial progenitor cell dysfunction [12]. Myeloperoxidase (MPO) is a bactericidal enzyme that is released from activated polymorphonuclear neutrophils and can directly modulate the vascular inflammatory response by regulating NO bioavailability [13]. Importantly, MPO also promotes HF following ischemic injury [14], atrial structural remodeling, and increases the risk of atrial fibrillation [15].

Mice with cardiomyocyte-specific deletion of iron-regulatory proteins (Irp) 1 and 2 exhibit mitochondrial dysfunction and accelerated HF after MI [16], which underscores the importance of iron availability in cardiomyocytes. This
Hier steht eine Anzeige.

Springer
is further emphasized by impaired mitochondrial capacity and contractility in human embryonic stem cell-derived cardiomyocytes following incubation with the iron chelator deferoxamine. Mitochondrial capacity and contractility were restored following enhanced intracellular iron levels, suggesting that iron levels directly mediate these effects [17]. It has been shown that LV samples from failing human hearts exhibit decreased iron content, which may impair mitochondrial capacity and ROS scavenging in these samples [18]. ROS can mediate both beneficial and deleterious effects that are based on the subcellular localization and duration of exposure to ROS, as recently reviewed [19].

The importance of inflammation in the development of HFpEF has been demonstrated in a swine model following induction of the three most common inflammation-associated comorbidities in HFpEF patients: arterial hypertension, diabetes mellitus, and hypercholesterolemia [20]. Diabetes mellitus also increases the risk of diastolic dysfunction and HF independent of coexisting coronary artery disease and hypertension. This resulted in the term “diabetic cardiomyopathy.” Various mechanisms increase the risk of HF in diabetic patients [21, 22], including increased inflammation. The underlying mechanisms of inflammatory-dependent HF in diabetic patients include increased expression levels of interleukins (IL-1β, IL-6), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), and decreased activity of the collagen degrading matrix metalloproteinase (MMP).

Finally, autophagy is a highly conserved cellular process that plays important roles in the maintenance of cellular homeostasis and quality control of organelles. Depending on the extent and duration of autophagy, this cellular process can be both beneficial and detrimental [23, 24]. Perturbed cardiac autophagy has been described for several risk factors of HFpEF development, including hypertension, diabetes, and aging [25].

**Inflammation following ischemic injury**

Macrophages and monocytes are essential for the inflammatory response and ventricular remodeling following ischemic injury [26, 27]. The cellular response to myocardial ischemia can be categorized into different phases: the acute inflammatory phase, the healing phase, and a phase of chronic inflammation. A schematic summary of these events after MI in mice is provided in \[\text{Fig. 2}\]. The different phases are well characterized in murine models and require a greater time span in larger animals and humans. The cellular and inflammatory adaptations are mediated by neutrophils and monocytes, which are generated in the bone marrow and the spleen and then translocate to the injured myocardium. Three monocyte subsets have been described in humans; these are based on the expression pattern of the surface protein expression markers CD14 and CD16. On the basis of these expression patterns, monocytes can be classified as classic (CD14++CD16–; murine homolog: Ly6C high), intermediate (CD14 ++CD16+), and nonclassic (CD14+CD16++; murine homolog: Ly6Clow) monocytes. Ly6C^high monocytes express high levels of Ly6C, CCR2, and CD62L and play a predominant role in the initial inflam-
matory phase after MI. Recruitment of Ly6C<sup>high</sup> monocytes is mediated by high expression levels of the cytokine CCL2. Ly6C<sup>high</sup> monocytes produce high levels of pro-inflammatory cytokines, such as IL-1β and tumor necrosis factor alpha (TNFα), which resulted in the term “inflammatory” monocytes for these cells. Ly6C<sup>high</sup> monocytes recruit inflammatory macrophages, which secrete proteolytic enzymes to digest and prepare the damaged tissue for regeneration. Inflammatory macrophages are commonly termed “M1” macrophages. Decreasing the recruitment of neutrophils to the injured myocardium is essential in order to limit tissue injury and to initiate the healing process. Following ingestion of damaged and apoptotic cells, macrophages decrease their production of IL-1β and TNFα, and increase the secretion of anti-inflammatory and pro-fibrotic cytokines, i.e., IL-10 and TGFβ [28]. Following transformation and change of their activation profile, less inflammatory macrophages are termed “M2” or “reparative” macrophages. Neutrophils play a critical role in this polarization of macrophages toward a reparative M2 phenotype [29]. Although commonly used, the categorization of macrophages into “M1” and “M2” subtypes is an oversimplification to describe their heterogeneity, which is originally based on in vitro studies and is problematic for describing adaptations in vivo.

The second phase, called the “healing phase,” is dominated by Ly6C<sup>low</sup> monocytes. These cells are recruited via CX3CR1 (fractalkine receptor)-mediated signaling to the infarcted region and are present at much lower numbers compared with Ly6C<sup>high</sup> monocytes [30]. Ly6C<sup>high</sup> can differentiate into Ly6C<sup>low</sup> monocytes. However, the exact relationship between M1 and M2 macrophages and Ly6C<sup>high</sup> and Ly6C<sup>low</sup> monocytes requires further investigation [31]. A seminal study performed by the Molkentin group greatly improved our understanding of how myocardial scar tissue forms after ischemic injury [32]. Using transgenic lineage-tracing mouse lines as reporter constructs, the authors show that both cardiomyocytes and fibroblasts die in the infarcted area. Subsequently, fibroblasts from the border zone region are activated and proliferate greatly, which results in an approximately 3.5-fold increase in the total number of fibroblasts in the infarcted area relative to uninjured conditions 3 days after MI. This elevation in count was observed for over 4 weeks. Between days 3 and 7, fibroblasts differentiate into myofibroblasts, as indicated by smooth muscle α-actin expression. Subsequently, the proliferation of myofibroblasts and smooth muscle α-actin expression decrease by days 7–10, while the scar tissue matures.

Following the healing phase, inflammation often persists or reoccurs during the development of HF. Hallmarks of chronic inflammation are the increased abundance of tissue T-lymphocytes and pro-inflammatory M1 macrophages [33, 34]. Risk factors for the development of cardiac inflammation has been suggested as an attractive target for the treatment of heart failure, which has been investigated in numerous clinical trials. This review discusses key inflammatory mechanisms contributing to the pathogenesis of heart failure and their potential impact as therapeutic targets.

**Key inflammatory mechanisms underlying heart failure**

**Abstract**

Inflammation plays a central role in the development of heart failure, especially in heart failure with preserved ejection fraction (HFpEF). Furthermore, the inflammatory response enables the induction of regenerative processes following acute myocardial injury. Recent studies in humans and animals have greatly advanced our understanding of the underlying mechanisms behind these adaptations. Importantly, inflammation can have both beneficial and detrimental effects, dependent on its extent, localization, and duration. Therefore, modulation of cardiac inflammation has been suggested as an attractive target for the treatment of heart failure, which has been investigated in numerous clinical trials. This review discusses key inflammatory mechanisms contributing to the pathogenesis of heart failure and their potential impact as therapeutic targets.

**Keywords**

Cardiac failure · Inflammation · Myocardial infarction · Immune system · Cytokine

**Entzündungsmechanismen bei Herzinsuffizienz**

**Zusammenfassung**

Entzündungsprozesse spielen eine zentrale Rolle bei der Entwicklung der Herzinsuffizienz, insbesondere bei Herzinsuffizienz mit erhhtener Ejektionsfraktion (HFpEF). Darüber hinaus sind Entzündungsprozesse allerdings auch für die Reparationsvorgänge nach akutem Myokardinfarkt erforderlich. Sowohl aktuelle Studien an Tiermodellen als auch Untersuchungen an Menschen führten zu einem besseren Verständnis der zugrunde liegenden Mechanismen. Abhängig von Lokalisation, Ausmaß und der Dauer können Entzündungsprozesse sowohl vorteilhaft als auch nachteilig sein. Deshalb bietet sich deren Beeinflussung als ein möglicher Angriffspunkt zur Behandlung der Herzinsuffizienz sowie pathologischer Umbauvorgänge an. Dies ist Gegenstand zahlreicher klinischer Studien. In der vorliegenden Übersichtsarbeit wird die Rolle wesentlicher Entzündungsprozesse in der Pathogenese der Herzinsuffizienz erörtert und deren potenzielle Bedeutung als Therapieoption diskutiert.

**Schlüsselwörter**

Herzinsuffizienz · Entzündung · Myokardinfarkt · Immunsystem · Zytokine
Atherosclerosis. A recent identified MI. Similarly, MI increases the risk of future ischemic events following MI. Inflammation is associated with an increased risk of ischemic injury. These effects are, at least in part, independent of systemic blood pressure and transduced by increased pro-inflammatory and pro-fibrotic signaling, i.e., TNFα, TGFβ, connective tissue growth factor (CTGF), and increased oxidative stress induced by NADPH oxidases [54–56]. Several studies using mouse models have advanced our understanding of cardiac MR-mediated signaling. Mice with genetic deletion of the MR in myeloid cells are protected against cardiac hypertrophy, fibrosis, and vascular damage induced by L-NAME/angiotensin II treatment.
Furthermore, these mice exhibit an alternatively activated M2 macrophage phenotype. This indicates that MR expression in myeloid cells is required for efficient classic macrophage activation by pro-inflammatory cytokines [57]. Genetic deletion of the MR in cardiomyocytes, but not in fibroblasts, attenuates contractile dysfunction and HF following pressure overload induced by transverse aortic constriction. However, MR deletion in cardiomyocytes or fibroblasts has no impact on cardiac fibrosis and hypertrophy relative to wild type controls following pressure overload [58]. This suggests a potential predominant role of MR expression in myeloid cells in this context. A series of studies performed by our laboratory has identified several MR-mediated cardioprotective mechanisms following MI. Treatment with the MR antagonist eplerenone attenuates adverse LV remodeling and contractile dysfunction in rats. The underlying mechanisms include accelerated macrophage infiltration, a transient increase in protective cytokines, and alternative M2 macrophage activation [59]. In this context, treatment with eplerenone is superior relative to spironolactone by increasing the abundance of healing Ly6C<sup>low</sup> monocytes and neovessel formation [60]. Additional mechanistic insight is provided by a transgenic mouse model with cardiomyocyte-specific MR deletion, which exhibits increased healing and attenuated contractile dysfunction [61]. In this model, MR deletion reduces infarct expansion and myocyte apoptosis, while infarct neovessel formation is increased in the early phase after ischemic damage. Furthermore, oxidative stress in the surviving LV myocardium is attenuated. This inflammatory cellular response is accelerated with a transient infiltration of neutrophils, which improves neovascularization and attenuates pathological remodeling. We also observed decreased expression of the MR target gene serum/glucocorticoid-regulated kinase 1 (SGK1) in MR-deficient cardiomyocytes, which mediates cardiomyocyte hypertrophy by increasing CTGF expression [62]. Notably, myeloid cell-specific MR deficiency also attenuates LV dysfunction.

| Study                        | Treatment         | Target       | Duration (months) | Clinical setting | NYHA class | n   | Primary outcome                        |
|------------------------------|-------------------|--------------|------------------|------------------|------------|-----|----------------------------------------|
| ATTACH [66]                  | Infliximab        | TNFα         | 7                | DCM, ICM         | III, IV    | 150 | ↑ Death and hospitalization for HF at high doses |
| RENEWAL (RECOVER and RENAISSANCE) [67] | Etanercept        | TNFα         | 5.7/12.9         | DCM, ICM         | II–IV      | 2048| ↔ Death and hospitalization rate for HF |
| Gullestad et al. [69]        | Thalidomide       | Multiple     | 3                | DCM, ICM         | II, III    | 56  | ↑ LVEF                                |
| Parrillo et al. [81]         | Prednisone        | Multiple     | 3                | DCM              | --         | 102 | ↑ LVEF                                |
| Skudicky et al. [70]         | Pentoxifylline    | Multiple     | 6                | DCM              | II, III    | 39  | ↑ LVEF and symptoms                    |
| Sliwa et al. [71]            | Pentoxifylline    | Multiple     | 6                | DCM              | II, III    | 28  | ↑ LVEF and symptoms                    |
| Sliwa et al. [72]            | Pentoxifylline    | Multiple     | 1                | DCM              | IV         | 18  | ↑ LVEF and ↓ TNFα                      |
| Sliwa et al. [73]            | Pentoxifylline    | Multiple     | 6                | ICM              | II, III    | 38  | ↑ LVEF and ↓ plasma inflammatory markers |
| Bahrmann et al. [74]         | Pentoxifylline    | Multiple     | 6                | DCM, ICM         | II, III    | 47  | ↔ LVEF                                |
| CORONA [75]                  | Rosuvastatin      | Multiple     | 32.8             | ICM              | II–IV      | 5011| ↔ Cardiovascular death, non-fatal MI, and nonfatal stroke |
| GISSI-HF [76]                | Rosuvastatin      | Multiple     | 46.9             | DCM, ICM         | II–IV      | 4574| ↔ Death and cardiovascular hospitalization |
| Krum et al. [77]             | Rosuvastatin      | Multiple     | 6                | DCM, ICM         | II–IV      | 87  | ↔ LVEF                                |
| ACCLAIM [78]                 | Device-based immunomodulation | Nonspecific | 10.2             | DCM, ICM         | II–IV      | 2426| ↔ Death and cardiovascular hospitalization |
| Gullestad et al. [79]        | Intravenous immunoglobulin | Multiple     | 6                | DCM, ICM         | II, III    | 40  | ↑ LVEF                                |
| IMETIC [82]                  | Methotrexate      | Multiple     | 3                | ICM              | II–IV      | 50  | ↔ 6-Minute walk test                  |

**ACCLAIM** Advanced Chronic Heart Failure Clinical Assessment of Immunomodulation, **ATTACH** Anti-TNF Therapy Against Congestive Heart Failure, **CORONA** Controlled Rosuvastatin Multinational Trial in Heart Failure, **DCM** dilated cardiomyopathy, **GISSI-HF** Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza cardiaca-Heart Failure, **HF** heart failure, **ICM** ischemic cardiomyopathy, **IMAC** Intervention in Myocarditis and Acute Cardiomyopathy, **LVEF** left-ventricular ejection fraction, **METIS** Methotrexate Therapy on the Physical Capacity of Patients with Ischemic Heart Failure, **MI** myocardial infarction, **RECOVER** Etanercept Cytokine Antagonism in Ventricular Dysfunction, **RENAISSANCE** Randomized Etanercept North American Strategy to Study Antagonism of Cytokines, **RENEWAL** Randomized Etanercept Worldwide Evaluation.
and LV remodeling following MI in mice by decreasing inflammation and oxidative stress [63]. Together, our studies identify a critical role of MR-transduced signaling to mediate tissue damage in ischemic heart injury. The mechanisms discovered include activation of inflammatory pathways in various cell types. Our studies also strongly support the importance of MR-antagonist treatment of patients with ischemic heart disease.

**Anti-inflammatory and immune-modulatory treatment of patients with HF**

Several clinical trials have tested the impact of anti-inflammatory and immune-modulatory therapies in patients with myocarditis, inflammatory cardiomyopathy, and HF [64, 65]. Despite this promising therapeutic approach, these studies have provided ambiguous results (Table 1). Based on its potential contribution to the progression of HF, the pro-inflammatory cytokine TNFα was identified as a promising pharmaceutical target. The randomized placebo-controlled ATTACH [66] and RENEWAL [67] trials tested the impact of the chimeric TNFα-antibody infliximab and the TNFα-inhibitor etanercept, respectively. The data obtained show no advantage of these treatments in patients with HF. Moreover, the ATTACH study reports adverse effects of infliximab at higher doses [66]. Potential mechanisms for these observations include binding of infliximab to TNFα-expressing cardiomyocytes, which might induce complement activation and cardiomyocyte apoptosis. Furthermore, administration of relatively high doses of infliximab might suppress TNFα below physiological concentrations, which are cardioprotective in the context of acute ischemic injury [68]. Gullestad and colleagues [69] recently described beneficial effects of the sedative and antinausea drug thalidomide. Despite the previously reported anti-inflammatory effects of thalidomide, the mechanisms are not completely understood and may include matrix stabilization based on decreased MMP2 expression.

Pentoxifylline is an anti-inflammatory agent that inhibits the production of TNFα and IL-6. Treatment with pentoxifylline increased LV contractile function and attenuates HF symptoms in some studies [70–73], while another report showed no difference [74]. Pentoxifylline is also a nonselective phosphodiesterase inhibitor. Therefore, pentoxifylline might mediate its cardioprotective effects by inhibiting phosphodiesterases and being, at least in part, independent of reducing inflammation. In addition to attenuating the formation of low-density lipoprotein by inhibiting the enzyme HMG-CoA reductase, statins are anti-inflammatory and improve endothelial function. However, treatment with statins is not beneficial in the context of HF unless administered in the presence of other comorbidities, such as dyslipidemia or coronary artery disease [75–77].

“Immunomodulation” therapy may provide a beneficial immune response to decrease pro-inflammatory and increase anti-inflammatory pathways. Patients with HF were subjected to “immunomodulation” by exposure of autologous blood ex vivo to controlled amounts of oxidative stress before administration by intragluteal injection. The ACCLAIM trial showed no impact of “immunomodulation” therapy on mortality and cardiovascular hospitalization [78]. Additional studies are required to understand the exact mechanisms of “immunomodulation” therapy that may contribute to potential positive effects of this treatment. In another study, HF patients were subjected to intravenous immunoglobulin (IVIg) infusions to modulate the immune response, which increased contractile function in patients with ischemic cardiomyopathy (ICM) and idiopathic dilated cardiomyopathy (DCM) [79]. By contrast, the IMAC trial [80] showed a similar increase in contractile function in patients with DCM or myocarditis who were treated with IVIg or placebo. It is important to note that the IMAC trial does not provide any data on histological sections from myocardial biopsies, inflammation, and viral persistence for a later time point. Thus, it is challenging to discern the potential benefits of IVIg therapy relative to standard HF therapy, which was administered to HF patients independent of IVIg or placebo. This is of particular importance for patients with myocarditis, who might benefit from the antiviral and immune-modulatory effects of IVIg therapy the most.

Additional therapeutic approaches to modulate the immune response in patients with HF include treatment with prednisone and methotrexate as well as by reduction in the abundance of auto-antibodies by immunoadsorption. In summary, the results of most studies targeting anti-inflammatory and immune-modulatory therapy are ambiguous. Table 1 summarizes major published clinical trials with anti-inflammatory and immune-modulatory treatment in patients with HF. Future research is warranted to identify additional targets for the modulation of inflammation in HF.

**Conclusion**

Inflammation plays a central role in the development of the different etiologies of HF, especially in HFP EF. Importantly, the inflammatory response following ischemic damage is also required to induce the regenerative response and is transduced by MR-mediated signaling. Decreased MR signaling is beneficial following ischemic damage because of the attenuation of pathological remodeling and MR antagonists are a well-established standard treatment for HF. A variety of key inflammatory markers have been identified that have been subsequently tested as potential targets for the treatment of HF. Even though clinical trials have provided inconclusive results, modulation of inflammation remains a promising target for the treatment of HF. Additional studies are required to further delineate the mechanisms and to identify novel target molecules, which is the subject of ongoing research in this field.
Hier steht eine Anzeige.

Springer
Compliance with ethical guidelines

Conflict of interest. C. Riehle received travel support from Abiomed. J. Bauersachs received honoraria for lectures and advice from Novartis, Pfizer, Vifor, Bayer, BMS, Servier, AstraZeneca, Orion, CVRx, Abiomed, Abbott, and Medtronic, and research support from Zoll, CVRx, Bayer, Vifor, Abiomed, and Medtronic.

This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bauersachs J, Maich B (2018) Heart failure 2.0 or 0.1? Herz 43(5):381–382. https://doi.org/10.1007/s00059-018-4720-4
2. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975. https://doi.org/10.1002/ejhf.592
3. Bleumink GS, Ketesh AM, Sturkenboom MC et al (2004) Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 25(18):1614–1619. https://doi.org/10.1093/euheartj/25.18.1614
4. Frantz S, Falcao-Pires J, Balligand JL et al (2018) The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. Eur J Heart Fail 20(3):445–459. https://doi.org/10.1002/ejhf.1138
5. Lourenço AP, Leite-Moreira AF, Balligand JL et al (2018) An integrative translational approach to study heart failure with preserved ejection fraction: A position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail 20(2):216–227. https://doi.org/10.1002/ejhf.1059
6. Paulus WJ, Tschape C (2013) A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271. https://doi.org/10.1016/j.jacc.2013.02.092
7. Fraccarollo D, Galuppo P, Motschenbacher S et al (2014) Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol 109(4):421. https://doi.org/10.1007/s00395-014-0421-1
8. Schafer A, Galuppo P, Fraccarollo D et al (2010) Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: Rescue by guanylyl-cyclase activation. Diabetes 59(9):2001–2009. https://doi.org/10.2337/db09-1668
9. Fraccarollo D, Widder JD, Galuppo P et al (2008) Improvement in left ventricular remodeling after infarction: the endothelial nitric oxide synthase enhancer AVF4988 after experimental myocardial infarction. Circulation 118(8):818–827. https://doi.org/10.1161/CIRCULATIONAHA.107.717702
10. Schafer A, Fraccarollo D, Widder J et al (2009) Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail 11(4):336–341. https://doi.org/10.1093/eurjhf/hfp005
11. Gevaert AB, Shakeri H, Leulous AJ et al (2017) Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003806
12. Thum T, Hoeber S, Froese S et al (2007) Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 100(3):434–443. https://doi.org/10.1161/01.RES.0000257912.78915.af
13. Escherich JP, Baldus S, Brennan ML et al (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296(5577):2391–2394. https://doi.org/10.1126/science.1070630
14. Askari AT, Brennan ML, Zhou X et al (2002) Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197(5):615–624
15. Rudolph V, Andrie RP, Rudolph TK et al (2010) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296(5577):2391–2394. https://doi.org/10.1126/science.1070630
16. Riehle C, Bauersachs J (2018) Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol 114(1):1. https://doi.org/10.1007/s00395-018-0711-0
17. Riehle C, Abel ED (2016) Insulin signaling and heart failure. Circ Res 118(7):1151–1169. https://doi.org/10.1161/CIRCRESAHA.116.308030
18. Zoll, CVRx, Bayer, Vifor, Abiomed, and Medtronic.

This work was supported by the German Research Foundation, Clinical Research Unit (KFO) 311. Figures were produced using templates from Servier Medical Art (www.servier.com).

Corresponding address

Prof. Dr. J. Bauersachs
Department of Cardiology and Angiology, Hannover Medical School
Carl-Neuberg-Str. 1, 30625 Hannover, Germany
bauersachs.johann@mh-hannover.de

Acknowledgements. This work was supported by the German Research Foundation, Clinical Research Unit (KFO) 311. Figures were produced using templates from Servier Medical Art (www.servier.com).

Compliance with ethical guidelines

Conflict of interest. C. Riehle received travel support from Abiomed. J. Bauersachs received honoraria for lectures and advice from Novartis, Pfizer, Vifor, Bayer, BMS, Servier, AstraZeneca, Orion, CVRx, Abiomed, Abbott, and Medtronic, and research support from Zoll, CVRx, Bayer, Vifor, Abiomed, and Medtronic.

This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
49. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199908183411001

50. Pitt B, Remme W, Zannad F et al (2001) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 345(14):1309–1321. https://doi.org/10.1056/NEJMoa003207

51. Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa109492

52. Adamopoulos C, Ahmed, A, Fay R et al (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: Insights from the EPHESUS trial. Eur J Heart Fail 11(11):1099–1105. https://doi.org/10.1093/ejhf/hfp136

53. Beygui F, Van Belle E, Ecolan P et al (2018) Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. Heart. https://doi.org/10.1136/heartjnl-2018-312950

54. Sun Y, Zhang J, Lu L et al (2004) Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 143(1):41–51. https://doi.org/10.1016/j.labcl.2003.11.002

55. Lopez-Andres N, Martin-Fernandez B, Rossignol P et al (2011) A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 301(6):H2372–2382. https://doi.org/10.1152/ajpheart.00283.2011

56. Johar S, Cave AC, Narayananpanicker A et al (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox-2 containing NADPH oxidase. FASEB J 20(9):1546–1548. https://doi.org/10.1096/fj.05-4628fe

57. Uher MG, Duan SZ, Ivaschenko CY et al (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120(9):3350–3364. https://doi.org/10.1172/JCI41080

58. Loather A, Berger S, Gildebach RT et al (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57(4):746–754. https://doi.org/10.1161/HYPERTENSIONAHA.110.163287

59. Fracarollo D, Galuppo P, Schraut S et al (2008) Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 51(4):905–914. https://doi.org/10.1161/HYPERTENSIONAHA.107.09941

60. Fracarollo D, Galuppo P, Sieweke JT et al (2015) Efficacy of mineralocorticoid receptor antagonist in the acute myocardial infarction phase: Eplerenone versus spironolactone. ESC Heart Fail 2(3):150–158. https://doi.org/10.1002/ehf2.12053

61. Fracarollo D, Berger S, Galuppo P et al (2011) Deletion of mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 124(4):400–408. https://doi.org/10.1161/CIRCULATIONAHA.110.983023

62. Vallon V, Wyatt AW, Klingen K et al (2006) SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med 84(5):396–404. https://doi.org/10.1002/jmm.20072

63. Fracarollo D, Thomas S, Scholz CJ et al (2018) Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing. Hypertension 71(1):102–111. https://doi.org/10.1161/HYPERTENSIONAHA.118.12162

64. Panahi M, Papanikolaou A, Torabi A et al (2018) Immunomodulatory interventions in myocardial infarction and heart failure: A systematic review of clinical trials and meta-analysis of II-1 inhibition. Cardiovasc Res 114(1):145–161. https://doi.org/10.1093/cvr/cvy145

65. Maisch B, Alter P (2018) Treatment options in myocarditis and inflammatory cardiomyopathy: Focus on I.v. immunoglobulins. Herz 43(5):423–430. https://doi.org/10.1007/s00059-018-4719-x

66. Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of in-fluximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25):3133–3140. https://doi.org/10.1161/01.CIR.0000124900.27666.BZ

67. Heymans S, Hirsch E, Anker SD et al (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11(2):119–129. https://doi.org/10.1093/ejhf/hfo043

68. Gullestad L, Ueland T, Fjeld KG et al (2005) Effect of thalidomide on cardiac remodeling in chronic heart failure. Results of a double-blind, placebo-controlled study. Circulation 112(22):3408–3414. https://doi.org/10.1161/CIRCULATIONAHA.105.564971

69. Skudicky D, Bergemann A, Siwa K et al (2001) Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: Results of a randomized study. Circulation 103(8):1083–1088

70. Siwa K, Skudicky D, Candy G et al (1998) Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351(9109):1091–1093. https://doi.org/10.1016/S0140-6736(97)06338-0

71. Siwa K, Woodwiss A, Candy G et al (2002) Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompressed congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 90(10):1118–1122

72. Siwa K, Woodwiss A, Kone VN et al (2004) Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: Results of a randomized study. Circulation 109(6):750–755. https://doi.org/10.1161/01.CIR.000012568.48387.60

73. Bahramm P, Hengst UM, Richartz BM, Figulla HR (2004) Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: Effects on left-ventricular function, inflammatory cytokines and...
Deutscher Herzbericht: Verbesserte Behandlungsmöglichkeiten führen zu einem Rückgang der Sterberate

Obwohl die Häufigkeit der Herzinsuffizienz anstieg, gelang es, die Sterberate von Herzinsuffizienz-Patienten um nahezu 11% zu senken. „Das ist natürlich ein großartiger Erfolg, der nicht ohne Grund erreicht wurde“, erklärt Katus. „Zum einen haben wir deutliche Fortschritte bei den Behandlungsmöglichkeiten sowohl im medikamentösen als auch im interventionellen und technologischen Bereich erreicht. Zum anderen konnten wir in der Ärztenschaft das Bewusstsein dafür verbessern, das für die Herzinsuffizienz und die damit einhergehenden Rhythmusstörungen bessere Behandlungsmöglichkeiten zur Verfügung stehen.“ So wurden mehr Patienten bei niedergelassenen Kardiologen und in den Kliniken vorstellig.

Zertifizierte Patientenversorgung

Die Etablierung spezialisierter und durch die DGK initiiert und zertifizierter Versorgungseinheiten, den sogenannten „Heart Failure Units“, hat ganz wesentlich zum Ziel, eine stationäre Behandlung in Deutschland dar. Dies wird voraussichtlich künftig weiter zunehmen. Der Qualitätsoffensive durch die Zertifizierung der DGK kommt somit auf dem Weg zu einer verbesserten Versorgung von Patienten mit Herzinsuffizienz eine enorme Wichtigkeit zu.

Ähnlich positive Behandlungserfolge können durch die nicht-invasive Herzklappenimplantation (TAVI) beim älteren Menschen mit erhöhtem Risiko berücksichtigt werden. Auch für die TAVIs hat die DGK gemeinsam mit der herzchirurgischen Fachgesellschaft DGTHG in Deutschland durch die Zertifizierung von spezialisierten TAVI-Zentren die Einhaltung von hohen qualitativen Standards initiiert und verbessert.

Weniger Herzinfarkte

Die DGK zeigt sich sehr erfreut, dass das Auftreten der ischämischen Herzkrankungen, also Ereignisse, die auf Durchblutungsstörungen am Herzen zurückzuführen sind, abgenommen haben (-2,2%). „Dies zeigt uns, dass unsere Präventionsstrategien zu greifen beginnen, und das finde ich sehr beeindruckend“, so der DGK-Präsident. „Dies ist das beste Beispiel für den hohen Stellenwert der Vorbeugung von Herz-Kreislauf-Krankheiten.“

Nach den großen Erfolgen in den Jahren zuvor ist die Sterberate nach einem Herzinfarkt jedoch seit einiger Zeit nahezu unverändert geblieben. Sie sank 2017 um nur 0,6%. „Wir scheinen hier ein Plateau erreicht zu haben. Dies zeigen uns auch Daten aus Schweden. Dort konnte die Sterblichkeit aufgrund eines Herzinfarktes zuletzt auch kaum noch gesenkt werden. Wir müssen daher neue alternative Therapieansätze entwickeln, um die Sterberate im Herzinfarkt noch weiter senken zu können“, fordert er.

Deutscher Herzbericht
Presstext DGK 02/2019